"The Report
Psoriasis - 5EU Drug Forecast and Market Analysis to 2024 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
Psoriasis
(PsO)
is an incurable genetic, systemic, inflammatory, and chronic skin
disorder with an overall prevalence of 2-3% worldwide. Specifically,
adult plaque psoriasis, the most common form of Psoriasis, is the
focus of this report. Although not life-threatening, Psoriasis causes
tremendous morbidity and personal angst for patients.
GlobalData
projects the Psoriasis market in 8MM to experience modest growth
during the forecast period at a CAGR of 7.26%. This growth will be
driven primarily by the highly anticipated arrivals of promising
systemic therapies- interleukin-17 (IL-17) inhibitors (Cosentyx,
guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors
(ixekizumab and brodalumab) as well as phsophodiesterase (PDE4)
inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries
of high-grossing branded drugs- especially TNF inhibitors, Humira,
Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain,
UK), and Japan, along with rapid global developmentsof biosimilars
are expected to spread the growth throughout the different classes of
products, away from the branded TNF inhibitors which have
traditionally been the main driver of growth in the prior years.
The
5EU contributed 31.6% of the global market share in the psoriasis
market in 2014. Similarly to the US, the drug classes spanning the
5EU psoriasis market were: TNF inhibitors, an IL-12/IL-23 inhibitor,
IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, a PDE-4
inhibitor, systemic therapies, biosimilars, and topical therapies.
Download Sample copy of this
Report at : http://www.marketresearchreports.biz/sample/sample/754851
Scope
-
Overview of Psoriasis including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
-
Detailed information on the key drugs in 5EU including product
description, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in 5EU from 2014-2024.
-
Analysis of the impact of key events as well the drivers and
restraints affecting 5EU Psoriasis market.
Reasons
to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for Psoriasis.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2014-2024 in 5EU.
Browse
Latest News at http://www.marketresearchreports.biz/articles
Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and
Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Treatment
Overview
4.1.1 Diagnosis
4.1.2 Leading Prescribed Drugs
and Treatment Guidelines
4.1.3 Clinical Practice
4.2 5EU
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor
Assessment
5.3 Product Profiles - Major
Brands
5.3.1 Enbrel (Etanercept)
5.3.2 Humira (Adalimumab)
5.3.3 Remicade (Infliximab)
5.3.4 Stelara (ustekinumab)
5.3.5 Cosentyx (Secukinumab)
5.3.6 Otezla (Apremilast)
5.3.7 Taclonex and Enstilar
(Calcipotriene and Betamethasone Dipropionate)
5.3.8 Methotrexate
5.3.9 Fumaderm (Fumaric Acid
Esters)
5.3.10 Alzumab (itolizumab)
5.3.11 Other Therapeutic Drug
Classes Used in Psoriasis
5.3.12 Non-pharmacological
Therapy
6 Unmet Need and Opportunity
6.1 Overview
6.2 Limited Patient Access Due
to Drug Reimbursement Pattern
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Improved Drug Safety and
Efficacy Profiles
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Education and Treatment of
Psychological Factors Accompanying Psoriasis
6.4.1 Unmet Need
6.4.2 Gap Analysis
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment